Table 2

Incidence of treatment-emergent adverse events occurring in >2 subjects in any treatment group

Adverse event	Placebo (N=27)	MOR103
Adverse event	Placebo (N=27)	0.3 mg/kg (N=24)	1.0 mg/kg (N=22)	1.5 mg/kg (N=23)	Pooled active (N=69)
Subjects with any treatment-emergent AE	12 (44.4)	13 (54.2)	14 (63.6)	15 (65.2)	42 (60.9)
Nasopharyngitis	3 (11.1)	1 (4.2)	7 (31.8)	1 (4.3)	9 (13.0)
RA*	0 (0.0)	3 (12.5)	4 (18.2)	2 (8.7)	9 (13.0)
Fatigue	1 (3.7)	1 (4.2)	4 (18.2)	1 (4.3)	6 (8.7)
Hypertension	1 (3.7)	1 (4.2)	2 (9.1)	2 (8.7)	5 (7.2)
Headache	1 (3.7)	1 (4.2)	0 (0.0)	2 (8.7)	3 (4.3)
Cough	0 (0.0)	1 (4.2)	0 (0.0)	2 (9.7)	3 (4.3)
Anaemia	0 (0.0)	0 (0.0)	0 (0.0)	2 (8.7)	2 (2.9)
Decreased D_Lco	2 (7.4)	2 (8.3)	0 (0.0)	0 (0.0)	2 (2.9)
Oropharyngeal pain	1 (3.7)	0 (0.0)	2 (9.1)	0 (0.0)	2 (2.9)
Rhinitis	0 (0.0)	0 (0.0)	2 (9.1)	0 (0.0)	2 (2.9)
Rhinorrhoea	0 (0.0)	0 (0.0)	0 (0.0)	2 (8.7)	2 (2.9)
Viral respiratory tract infection	0 (0.0)	0 (0.0)	0 (0.0)	2 (8.7)	2 (2.9)
Peripheral oedema	2 (7.4)	0 (0.0)	1 (4.5)	0 (0.0)	1 (1.4)
Rash	3 (11.1)	1 (4.2)	0 (0.0)	0 (0.0)	1 (1.4)
Upper respiratory tract infection	2 (7.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Urinary tract infection	3 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Values shown are number (%) of subjects with events.
*Worsening or exacerbation of existing RA (flares). Except for one patient in the MOR103 0.3 mg/kg group (date of flare not reported), all events occurred from 10 days to >12 weeks following the last dose of active treatment.
AE, adverse event; D_Lco, diffusing capacity of the lung for carbon monoxide; RA, rheumatoid arthritis.